Latest Insider Transactions at Five Prime Therapeutics, Inc. (FPRX)
This section provides a real-time view of insider transactions for Five Prime Therapeutics, Inc. (FPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FIVE PRIME THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FIVE PRIME THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 16
2021
|
Thomas Civik President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68,971
-100.0%
|
$2,620,898
$38.0 P/Share
|
|
Apr 16
2021
|
Franklin M Berger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
$190,000
$38.0 P/Share
|
|
Apr 16
2021
|
David White Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,423
-100.0%
|
$1,270,074
$38.0 P/Share
|
|
Apr 16
2021
|
David V Smith Executive Vice President & CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
138,947
-100.0%
|
$5,279,986
$38.0 P/Share
|
|
Apr 16
2021
|
David V Smith Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
66,000
+32.2%
|
-
|
|
Apr 16
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,385
-100.0%
|
$90,630
$38.0 P/Share
|
|
Apr 16
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
169,468
-100.0%
|
$6,439,784
$38.0 P/Share
|
|
Apr 16
2021
|
Francis Willard Sarena Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,000
+28.03%
|
-
|
|
Apr 16
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
135,547
-100.0%
|
$5,150,786
$38.0 P/Share
|
|
Apr 16
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,000
+32.75%
|
-
|
|
Apr 09
2021
|
Thomas Civik President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,088
-13.85%
|
$410,256
$37.94 P/Share
|
|
Apr 06
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
14,174
-12.05%
|
-
|
|
Apr 05
2021
|
William R Ringo Director |
SELL
Bona fide gift
|
Direct |
10,000
-100.0%
|
-
|
|
Apr 05
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
2,460
-2.05%
|
-
|
|
Apr 01
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
3,825
-1.55%
|
-
|
|
Apr 01
2021
|
Francis Willard Sarena Chief Strategy Officer |
BUY
Bona fide gift
|
Indirect |
2,385
+50.0%
|
-
|
|
Mar 31
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
8,085
-10.41%
|
-
|
|
Feb 28
2021
|
David White Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,461
-4.19%
|
$32,142
$22.23 P/Share
|
|
Feb 26
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,158
-1.47%
|
$25,476
$22.23 P/Share
|
|
Feb 26
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,158
-0.93%
|
$25,476
$22.23 P/Share
|
|
Feb 25
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,653
-2.05%
|
$38,019
$23.08 P/Share
|
|
Feb 25
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,653
-1.31%
|
$38,019
$23.08 P/Share
|
|
Feb 24
2021
|
David White Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-3.2%
|
$28,875
$25.71 P/Share
|
|
Feb 24
2021
|
David V Smith Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,110
-6.55%
|
$127,750
$25.71 P/Share
|
|
Feb 24
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,091
-5.95%
|
$127,275
$25.71 P/Share
|
|
Feb 24
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,100
-3.88%
|
$127,500
$25.71 P/Share
|
|
Dec 11
2020
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,583
-11.93%
|
$185,328
$16.14 P/Share
|
|
Dec 11
2020
|
Helen Louise Collins EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+18.47%
|
-
|
|
Dec 11
2020
|
David V Smith Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,504
-12.84%
|
$184,064
$16.14 P/Share
|
|
Dec 11
2020
|
David V Smith Executive Vice President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+19.72%
|
-
|
|
Dec 11
2020
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,583
-8.39%
|
$185,328
$16.14 P/Share
|
|
Dec 11
2020
|
Francis Willard Sarena Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+13.75%
|
-
|
|
Nov 26
2020
|
David V Smith Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,920
-9.29%
|
$124,560
$18.45 P/Share
|
|
Nov 11
2020
|
William R Ringo Director |
SELL
Open market or private sale
|
Direct |
78,959
-78.17%
|
$1,737,098
$22.5 P/Share
|
|
Nov 11
2020
|
William R Ringo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78,959
+43.81%
|
$157,918
$2.51 P/Share
|
|
Nov 11
2020
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,039
-12.81%
|
$198,702
$18.0 P/Share
|
|
Nov 11
2020
|
Helen Louise Collins EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+20.34%
|
-
|
|
Nov 11
2020
|
David V Smith Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,908
-12.77%
|
$196,344
$18.0 P/Share
|
|
Nov 11
2020
|
David V Smith Executive Vice President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+20.49%
|
-
|
|
Nov 11
2020
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,001
-8.66%
|
$198,018
$18.0 P/Share
|
|
Nov 11
2020
|
Francis Willard Sarena Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+14.76%
|
-
|
|
Nov 11
2020
|
Bvf Partners L P |
SELL
Open market or private sale
|
Direct |
7,393,340
-85.8%
|
$147,866,800
$20.19 P/Share
|
|
Nov 06
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
30,000
+0.36%
|
$120,000
$4.98 P/Share
|
|
Nov 04
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
416,562
+3.97%
|
$1,666,248
$4.88 P/Share
|
|
Oct 06
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
345,241
+4.16%
|
$1,726,205
$5.04 P/Share
|
|
Sep 30
2020
|
David White Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,916
-16.1%
|
$27,664
$4.7 P/Share
|
|
Sep 22
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
32
+0.01%
|
$96
$3.8 P/Share
|
|
May 14
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
293,587
+2.57%
|
$1,174,348
$4.1 P/Share
|
|
Dec 20
2019
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
515,020
+6.18%
|
$2,060,080
$4.05 P/Share
|
|
Dec 09
2019
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
135,000
+1.38%
|
$540,000
$4.02 P/Share
|